UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)				April 1430, 2020
BIOELIFE CORP.
(Exact name of registrant as specified in its charter)
Nevada	000-55604				98-0514250
(State or other jurisdiction of incorporation)	(Commission File Number)				(IRS Employer Identification No.)
12340 Seal Beach Blvd. Suite B-190 Seal Beach, CA				90740
(Address of principal executive offices)			(Zip Code)
Registrant’s telephone number, including area code		(702) 866-2500
N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.
Title of each class	Trading Symbol(s)	Name of each exchange on which registered


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
			Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

ITEM 84.01 ~~OTHER~~CHANGES ~~EVENTS~~IN REGISTRANT’S CERTIFYING ACCOUNTANT

On ~~March~~April 1230, 2020, ~~BioELife~~Sadler, ~~Corp.~~Gibb ~~(the~~& Associates, LLC (“~~Company~~Sadler Gibb”), ~~issued~~resigned aits ~~press~~position ~~release~~as ~~announcing~~the ~~that~~independent itpublic ~~would~~accountant beengaged ~~adding ultra-protective nano fiber face masks manufactured by Respilon~~ to ~~its~~audit ~~product~~BioELife ~~line~~Corp.’s ~~with~~financial ~~anticipated~~statements ~~availability~~for in the ~~first~~year ~~week~~ended ofDecember ~~April.~~31, 2019.

OnSadler ~~April~~Gibb ~~14,~~did ~~2020,~~not ~~however,~~conduct ~~the~~an ~~Company~~audit ~~was~~or ~~informed~~issue ~~that~~an ~~the~~audit ~~manufacturer~~report isfor ~~unable~~BioELife tofor ~~fulfill~~ the ~~Company’s~~past ~~order~~two years, and ~~will~~therefore, beSadler ~~returning~~Gibb ~~the~~has ~~purchase~~not ~~price~~issued toan ~~the~~audit ~~Company.~~report ~~Accordingly,~~in the ~~Company~~past ~~does~~two ~~not~~years ~~currently~~that ~~expect~~contained toan beadverse ~~able~~opinion toor ~~deliver~~a ~~Respilon~~disclaimer ~~face~~of ~~masks~~opinion, ~~and~~or ~~will~~was bequalified ~~making~~or ~~refunds~~modified as to ~~customers~~uncertainty, ~~that~~audit ~~have~~scope, ~~pre-ordered~~or ~~them~~accounting principles.

OnDuring ~~April~~its 8,engagement ~~2020,~~by the ~~United~~Company, ~~States~~Sadler ~~Securities~~Gibb ~~and~~has ~~Exchange~~not ~~Commission~~issued ~~(the~~any ~~“SEC”)~~audit ~~announced~~reports aon ~~temporary suspension of trading of~~ the ~~Company’s~~financial ~~common~~statements ~~stock citing “questions and concerns regarding the accuracy and adequacy~~ of ~~publicly available information” about~~ the Company, ~~including “press releases issued on March 12, 2020,~~ and ~~March~~there ~~16,~~were ~~2020,~~no ~~and~~disagreements ~~reinforced by third-party stock promoters . . . together~~ with ~~potentially~~Sadler ~~manipulative~~Gibb ~~trading~~on ~~activity~~any ~~between~~matter ~~October~~of ~~2019~~accounting ~~and~~principles ~~the~~or ~~present.”~~practices, ~~The~~financial ~~Company~~statement ~~has~~disclosure ~~initiated~~or anauditing ~~internal~~scope ~~investigation~~or ~~examining the matters raised by the SEC~~procedure.

~~SIGNATURES~~BioELife has provided Sadler Gibb with a copy of the disclosures it is making in this Current Report on Form 8-K and has requested that Sadler Gibb furnish BioELife with a letter addressed to the Commission stating whether it agrees with the statements made by BioELife in this report and, if not, stating the respects in which it does not agree. A copy of the letter from Sadler Gibb addressed to the Securities and Exchange Commission dated May 5, 2020 is filed as Exhibit 16.01 to this Current Report on Form 8-K.

~~Pursuant~~ITEM to9.01. ~~the~~FINANCIAL ~~requirements~~STATEMENTS ofAND ~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~EXHIBITS

~~BIOELIFE~~The ~~CORP.~~following ~~/s/~~is ~~Gregory~~filed ~~Rotelli~~as ~~Gregory~~an ~~Rotelli~~exhibit ~~President~~to ~~and~~this ~~Chief Executive Officer Date~~report: ~~April 17, 2020~~

Exhibit Number	Title of Document	Location

Item 16	Letter on Change in Certifying Accountant
16.01	Letter from Sadler, Gibb & Associates, LLC. to Securities and Exchange Commission regarding change in certifying accountant dated May 5, 2020	This filing

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOELIFE CORP.

/s/ Gregory Rotelli

Gregory Rotelli

President and Chief Executive Officer

Date: May 6, 2020

Filing Compare · U.S. Lithium Corp.